Cargando…

Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in E-TCL1 mice

Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor approved for the treatment of multiple B-cell malignancies, including chronic lymphocytic leukemia (CLL). In addition to blocking B-cell receptor signaling and chemokine receptor-mediated pathways in CLL cells, that are known drivers of disease...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hanna, Bola S., Yazdanparast, Haniyeh, Demerdash, Yasmin, Roessner, Philipp M., Schulz, Ralph, Lichter, Peter, Stilgenbauer, Stephan, Seiffert, Martina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017821/ https://www.ncbi.nlm.nih.gov/pubmed/32139435 http://dx.doi.org/10.3324/haematol.2019.238154

Ejemplares similares

IDO1-Targeted Therapy Does Not Control Disease Development in the Eµ-TCL1 Mouse Model of Chronic Lymphocytic Leukemia
por: Öztürk, Selcen, et al.
Publicado: (2021)

Simultaneous Inhibition of PI3Kgamma and PI3Kdelta Deteriorates T-cell Function With Implications for Chronic Lymphocytic Leukemia
por: Faehling, Sebastian, et al.
Publicado: (2023)

Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia
por: Kater, Arnon P., et al.
Publicado: (2021)

EOMES is essential for antitumor activity of CD8(+) T cells in chronic lymphocytic leukemia
por: Llaó-Cid, Laura, et al.
Publicado: (2021)

T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?
por: Roessner, Philipp M., et al.
Publicado: (2020)

Publisher Correction: T cells in chronic lymphocytic leukemia: guardians or drivers of disease?
por: Roessner, Philipp M., et al.
Publicado: (2021)

Tumor necrosis factor receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin
por: Dürr, Claudia, et al.
Publicado: (2018)

Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients
por: Öztürk, Selcen, et al.
Publicado: (2021)

TIGIT: an immune checkpoint beyond T cells in chronic lymphocytic leukemia
por: Seiffert, Martina
Publicado: (2023)

Dissecting the Prognostic Significance and Functional Role of Progranulin in Chronic Lymphocytic Leukemia
por: Schulze-Edinghausen, Lena, et al.
Publicado: (2019)

CD4+ T cells, but not non-classical monocytes, are dispensable for the development of chronic lymphocytic leukemia in the TCL1-tg murine model
por: Kocher, T, et al.
Publicado: (2016)

EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4(+) T cells in chronic lymphocytic leukemia
por: Roessner, Philipp M., et al.
Publicado: (2021)

Effective Tcl/Tk programming: writing better programs with Tcl and Tk
por: Harrison, Mark, et al.
Publicado: (1998)

HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model
por: Maharaj, Kamira, et al.
Publicado: (2020)

p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL
por: Lee, H J, et al.
Publicado: (2016)

Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy
por: Zapatka, Marc, et al.
Publicado: (2021)

Tcl and the Tk toolkit /
por: Ousterhout, John K.
Publicado: (1994)

Tcl and the Tk toolkit
por: Ousterhout, John K
Publicado: (1994)

Tcl/Tk tools
por: Harrison, M, et al.
Publicado: (1997)

Tcl and the Tk toolkit
por: Ousterhout, John K, et al.
Publicado: (2009)

Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
por: Puła, Bartosz, et al.
Publicado: (2019)

Bone Reconstruction in Chronic Lymphocytic Leukemia with Ibrutinib
por: Koba, Yusuke, et al.
Publicado: (2023)

Practical programming in Tcl and Tk
por: Welch, Brent B, et al.
Publicado: (2003)

Tcl/Tk in a Nutshell
por: Raines, Paul, et al.
Publicado: (2009)

Practical programming in Tcl and Tk
por: Welch, Brent B
Publicado: (1995)

Tcl 85 Network Programming
por: Kocjan, Wojciech, et al.
Publicado: (2010)

TclTk Pocket Reference
por: Raines, Paul
Publicado: (1998)

Practical programming in Tcl & Tk
por: Welch, Brent B
Publicado: (2000)

Functional Analysis of Tcl1 Using Tcl1-Deficient Mouse Embryonic Stem Cells
por: Miyazaki, Tatsushi, et al.
Publicado: (2013)

TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemia
por: Szenes, Eva, et al.
Publicado: (2020)

Evidence for Non-Cancer-Specific T Cell Exhaustion in the Tcl1 Mouse Model for Chronic Lymphocytic Leukemia
por: Parigger, Thomas, et al.
Publicado: (2021)

DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy
por: Yosifov, Deyan Yordanov, et al.
Publicado: (2020)

Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?
por: Aydin, Ebru, et al.
Publicado: (2021)

Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2019)

Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia
por: Kidoguchi, Keisuke, et al.
Publicado: (2021)

Correction: Functional Analysis of Tcl1 Using Tcl1-Deficient Mouse Embryonic Stem Cells
por: Miyazaki, Tatsushi, et al.
Publicado: (2013)

Crystal Structure of Murine Tcl1 Oncoprotein and Conserved Surface Features of the Molecules of the Tcl1 Family
por: Petock, John M., et al.
Publicado: (2002)

A novel cloning strategy for one-step assembly of multiplex CRISPR vectors
por: Zuckermann, Marc, et al.
Publicado: (2018)

TcL Scripting for Cisco IOS
por: Blair, Raymond, et al.
Publicado: (2010)

TclTk 85 Programming Cookbook
por: Wheeler, Bert
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_f4d3e3uhvpbitgoci325bok4qe